ArticleMaterials today. Bio2025
Engineered vesicles facilitate the programmed transdermal-intestinal delivery of cinnabar for insomnia mitigation by modulating serotonin-Htr1d-cAMP.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insomnia is a prevalent sleep disorder and it affects brain development, with pediatric populations being particularly vulnerable. Cinnabar, a mineral drug composed of HgS, has demonstrated efficacy in alleviating insomnia through suppressing the overactivity of glutamate receptors (NMDA/AMPA), etc. However, oral administration of cinnabar poses risks, including binding with hemoglobin and accumulation in tissues and organs, resulting in neurotoxicity. To overcome these limitations, we developed a novel transdermal and intestinal targeting programmed nanoplatform for cinnabar delivery (TAT/CSK-cinnabar vesicle, TCCV), of which, cinnabar was encapsulated within a lipid vesicle, which was then co-engineered with cell-penetrating peptide TAT and the intestinal-targeting CSK ligand. Accordingly, TCCV showed exceptional sequential penetration through the stratum corneum (SC) and intestinal barriers, and also actively targeted intestinal goblet cells with a 15-fold increase in efficiency compared to non-engineered vesicles. Furthermore, TCCV forms a reservoir releasing cinnabar at the intestinal site with controlled manner, significantly reducing fluctuations in cinnabar concentration in blood and organs, thereby reducing toxicity. In current anti-insomnia studies, TCCV exhibited predominantly enhanced therapeutic efficiency compared to the oral control group, with drug efficiency increased by 1.5 to 2.5-fold. With the analysis of RNA sequencing and 16S rRNA, the regulation of the serotonin (5-HT) production in gut microbes and activating the Htr1d-cAMP pathway of cerebral cortex through the "brain-gut axis" by TCCV is identified as the novel mechanism for the insomnia mitigation effect of cinnabar. This study offers a novel non-invasive transdermal and targeted nanoplatform that significantly improves the efficacy and biosafety of cinnabar delivery and highlights a new gut-brain axis-mediated mechanism in insomnia mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.